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Background
We present the winding, progressively aggravating evolu-
tion of a 70 year-old patient, with multiple risk factors
(arterial hypertension, NYHA class II/III heart failure,
atrial fibrillation, sequelar stroke, bladder AK, treated with
chemotherapy, urinary catheter carrier) who developed
sepsis of multiple bacterial etiology – MDR “hospital”
Gram-negative bacilli (GNB) and fungi.
Case report
We present the patient evolution, who in February 2014,
following emergency surgery for occlusive syndrome
presented severe cardiac decompensation and MDR
GNB bronchopneumonia requiring advanced support of
vital functions and various combinations of antibiotics
(ABT) decided in the ICU. After 32 days of complex
therapeutic efforts and support of vital functions (neuro-
logical, respiratory, heart, kidney and liver), the patient
was extubated but the febrile syndrome recurred, and
the biological and imaging data demonstrated a septic
evolutionary process. The positive cultures for P. aerugi-
nosa, A. baumannii, K. pneumoniae, all MDR and Can-
dida spp., in conjunction with biological and PCQT
changes required infectious diseases consultation. The
recommend therapy: meropenem + colimycin + linezo-
lid + fluconazole in adequate dose.
The evolution of the infectious process appeared to be
controlled without fever after 24h of treatment and the
procalcitonin level decreased. Our patient was transferred
for further ABT + AFT (antifungal therapy). During hospi-
talization in the ICU of INBI the patient continued ABT +
AFT, slowly evolving favorably and we obtained: evidence
of negative microbial cultures, without fever, in the
absence of ABT and AFT (for a period of 12 days).
The patient presented a new episode of sepsis caused
by K. pneumoniae – PDR (carbapenemase positive) with
positive urine and blood cultures. Reintroduction of a
new “rescue” ABT scheme – meropenem + tigecycline +
colimycin, with microbiologic control proving the off-
label dosing.
Conclusion
In the era of microbial resistance we believe that inter-
disciplinary team decisions are absolutely mandatory
from the start, especially in the critically ill patient,
requiring associations ABT ± AFT, strictly individua-
lized, often including off-label doses that require specia-
lized expertise. Despite the efforts made and the
evidence of microbiological control, as it was likely to
happen due to comorbidities and severity of vital organ
dysfunction, the patient developed severe heart rhythm
disorder followed by exitus. So, in patients with severe
immunosuppression, we are continuously forced to
maximize therapy regardless of pan-resistance in vitro
and trying, at the least, to demonstrate control of the
septic process.
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